Evidence map›Paper›PMID 34109128›Full record

ReviewFrontiers in oncology2021

Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy.

Isabella Giacomini, Federico Gianfanti, Maria Andrea Desbats, Genny Orso, Massimiliano Berretta, Tommaso Prayer-Galetti, Eugenio Ragazzi, Veronica Cocetta

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Harnessing mMolecular medicine (Cambridge, Mass.) · 2025
    Article
  11. Article
  12. Review
  13. 27-Hydroxycholesterol in cancer development and drug resistance.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Isabella GiacominiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Federico GianfantiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Maria Andrea DesbatsVeneto Institute of Molecular Medicine, VIMM, Padova, Italy.
Genny OrsoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Massimiliano BerrettaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Tommaso Prayer-GalettiDepartment of Surgery, Oncology and Gastroenterology - Urology, University of Padova, Padova, Italy.
Eugenio RagazziDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
Veronica CocettaDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
University of Padua · ITVeneto Institute of Molecular Medicine · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholesterol is a ubiquitous sterol with many biological functions, which are crucial for proper cellular signaling and physiology. Indeed, cholesterol is essential in maintaining membrane physical properties, while its metabolism is involved in bile acid production and steroid hormone biosynthesis. Additionally, isoprenoids metabolites of the mevalonate pathway support protein-prenylation and dolichol, ubiquinone and the heme

Indexed as

cancercancer therapycholesterolmetabolic reprogrammingmetabolic targeting agentspharmacological modulationpharmacological targeting

Identifiers

PMID34109128
PMCPMC8181394
OpenAlexW3165374111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.